T1	Participants 898 966	Forty-six patients were randomized in arm A and 45 patients in arm B
T2	Participants 589 824	In arm A, patients received 12-week bevacizumab plus 5-FU, leucovorin and oxaliplatin (Folfox-4) followed with bevacizumab-5-FU-RT before total mesorectal excision (TME). In arm B, patients received only bevacizumab-5-FU-RT before TME.
